Boston Scientific Co. (NYSE:BSX) EVP Sells $539,785.90 in Stock

Boston Scientific Co. (NYSE:BSX) EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $77.30, for a total transaction of $539,785.90. Following the transaction, the executive vice president now directly owns 42,908 shares in the company, valued at approximately $3,316,788.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Wendy Carruthers also recently made the following trade(s):

• On Monday, June 3rd, Wendy Carruthers sold 6,983 shares of Boston Scientific stock. The shares were sold at an average price of $75.33, for a total transaction of $526,029.39.

Boston Scientific Stock Performance

NYSE:BSX opened at $76.11 on Thursday. The firm has a market capitalization of $111.66 billion, a PE ratio of 63.96, a PEG ratio of 2.65 and a beta of 0.78. The stock’s fifty day moving average is $75.16 and its 200 day moving average is $67.96. Boston Scientific Co. has a fifty-two week low of $48.35 and a fifty-two week high of $77.99. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.05. The business had revenue of $3.86 billion for the quarter, compared to analysts’ expectations of $3.68 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. On average, sell-side analysts anticipate that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on BSX. Robert W. Baird increased their price target on Boston Scientific from $79.00 to $84.00 and gave the stock an “outperform” rating in a research note on Thursday, April 25th. Mizuho increased their target price on Boston Scientific from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. The Goldman Sachs Group assumed coverage on Boston Scientific in a report on Thursday, May 30th. They issued a “buy” rating and a $90.00 price target on the stock. JPMorgan Chase & Co. upped their price target on Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $82.00 price objective on shares of Boston Scientific in a research report on Tuesday, June 18th. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $77.41.

Institutional Trading of Boston Scientific

Institutional investors have recently added to or reduced their stakes in the company. Massmutual Trust Co. FSB ADV raised its holdings in shares of Boston Scientific by 17.7% in the second quarter. Massmutual Trust Co. FSB ADV now owns 4,690 shares of the medical equipment provider’s stock worth $361,000 after buying an additional 705 shares during the period. First Hawaiian Bank grew its position in Boston Scientific by 13.6% in the 2nd quarter. First Hawaiian Bank now owns 55,859 shares of the medical equipment provider’s stock valued at $4,302,000 after acquiring an additional 6,668 shares during the last quarter. GAMMA Investing LLC increased its stake in Boston Scientific by 29.7% in the second quarter. GAMMA Investing LLC now owns 12,460 shares of the medical equipment provider’s stock worth $960,000 after purchasing an additional 2,854 shares during the period. Transcend Capital Advisors LLC lifted its position in shares of Boston Scientific by 2.2% during the second quarter. Transcend Capital Advisors LLC now owns 6,773 shares of the medical equipment provider’s stock worth $522,000 after purchasing an additional 148 shares during the last quarter. Finally, Bank of New Hampshire purchased a new stake in shares of Boston Scientific during the second quarter valued at $113,000. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.